RA CAPITAL MANAGEMENT, L.P. purchased $1.4M of ARTV (indirect holdings)
RA CAPITAL MANAGEMENT, L.P. purchased 160,354 indirectly-held shares of Artiva Biotherapeutics, Inc. (ARTV) at an average of $8.93 ($8.93–$8.95, $1.43M total) across 2 trades over 2026-07-16 to 2026-07-17.
How this was made
The 30-second read
Why it matters
The newest fact is the specific open-market purchase amount, share count, and price range, which may modestly influence sentiment but does not change ARTV’s fundamentals based on the provided text.
Market read
Traders may note the disclosed buying as a small sentiment input, but there is no accompanying catalyst in the text.
What to watch
The filing notes no pre-arranged 10b5-1 plan, but the article does not provide intent, holding horizon, or whether the fund’s stake is part of a broader strategy.
Background
The article is a SEC Form 4 insider transaction disclosure, where RA Capital Management, L.P. is listed as a director and 10% owner with an indirect position in Artiva Biotherapeutics.
Ticker impact
RA Capital Management, L.P. reported an open-market purchase of 160,354 shares of Artiva Biotherapeutics (ARTV) for about $1.43M on 2026-07-16 to 2026-07-17.
Likely limited near-term impact; any effect would be sentiment-driven rather than fundamental.
Form 4 provides a fresh, specific transaction size and price range, but it does not include new company guidance, trial results, contracts, or regulatory actions.
Market effects
No direct sector read-through; this is a single-issuer Form 4 transaction.
None indicated.
None indicated.
Counterpoint
Indirect purchases by a large holder can reflect portfolio rebalancing or liquidity needs rather than a conviction signal about near-term fundamentals.
Key entities
- issuerArtiva Biotherapeutics, Inc.
Subject of the Form 4 disclosure, ticker ARTV.
- reporterRA Capital Management, L.P.
Reported the indirect open-market purchase totaling about $1.43M.